BrainStorm Cell Therapeutics has received a notice of allowance from the US Patent Office for its ‘Mesenchymal Stem Cells for the Treatment of CNS Diseases’ (serial number 12/994,761) patent application.
This patent relates to BrainStorm's proprietary stem cells induced to secrete large quantities of neurotrophic factors for the treatment of neurodegenerative diseases.
Pending approval from the US Food and Drug Administration, the company is currently preparing for its upcoming multi-center Phase II trial in the US with its proprietary NurOwn stem cell therapy, which was developed with these cells.
BrainStorm president and principal executive officer Chaim Lebovits noted following the recent notices of allowance from both the US and European Patent Offices for the company's production method, this key patent allowance for our unique cells significantly enhances our IP portfolio.
"It represents a strong vote of confidence in our technology as we pursue our clinical trials program both in Israel and the US," Lebovits added.
BrainStorm is the exclusive worldwide licensee of this technology from Ramot, the technology transfer company of Tel Aviv University, where it was developed by Professors Daniel Offen and Eldad Melamed, in conjunction with BrainStorm's scientists.
